10X Genomics (TXG) Q4 2025: Spatial Consumables Surge 14% as Xenium Drives Portfolio Shift
Xenium-fueled spatial consumables growth and robust Flex Apex adoption signal a strategic pivot toward high-volume, AI-driven research despite persistent instrument headwinds. Management’s focus on translational and clinical market expansion, alongside disciplined cost controls, positions TXG for resilience as funding volatility lingers. Investors should watch the evolving balance between volume-driven consumables growth and margin dilution from pricing shifts in 2026.
Summary
- Xenium Dominance in Spatial: Rapid spatial consumables expansion reflects Xenium’s outperformance and shifting customer preference.
- Flex Apex Adoption Accelerates: New single-cell assay drives double-digit reaction growth and broadens use cases.
- Translational Push Gains Traction: Biopharma and clinical initiatives set the stage for future revenue diversification.
Business Overview
10X Genomics (TXG) develops and sells advanced genomics solutions that enable high-resolution, single-cell and spatial biology research. The company’s core revenue streams are consumables, recurring reagents and kits used in experiments, and instruments, the capital equipment platforms that run these assays. Its major product lines include Chromium (single-cell), Visium (spatial), and Xenium (next-generation spatial), with an increasing focus on serving translational research and clinical markets alongside traditional academic and pharma customers.
Performance Analysis
Q4 2025 results underscore a clear divergence between consumables strength and ongoing capital equipment headwinds. While total revenue growth was modest, consumables outperformed: single-cell consumables rose on the back of >30% reaction volume growth, largely due to the launch of Flex Apex, a next-generation assay that expands both access and use cases. Spatial consumables, driven entirely by Xenium, surged 14% year-over-year, outpacing legacy Visium, which saw no growth.
Instrument revenue, however, declined sharply—36% overall—with Chromium instruments down 44% and spatial instruments down 30%, reflecting persistent CapEx constraints in customer budgets. Regional trends were mixed: Americas contracted 6% while EMEA and APAC delivered mid to high single-digit growth, aided by late-quarter budget flushes. Gross margin improved to 68%, benefiting from lower inventory write-downs and cost discipline, while operating expenses fell 18% on reduced legal and personnel costs, lifting cash reserves by $130 million year-over-year.
- Consumables Volume Expansion: Single-cell reaction growth exceeded 30% in Q4, offsetting price headwinds from Flex Apex adoption.
- Spatial Mix Shift: Xenium now drives all spatial consumables growth, with Visium flat, signaling a portfolio realignment.
- Instrument Weakness Persists: Ongoing CapEx funding constraints led to double-digit instrument declines, a trend expected to persist into 2026.
The interplay between high-volume consumables growth and lower average selling prices will be a key dynamic for margins and revenue mix in 2026.
Executive Commentary
"Flex Apex combines exceptionally high performance with flexible inputs, including compatibility with FFP and fixed whole blood. It supports both small exploratory experiments as well as ones with high sample counts and large numbers of cells, making it well-suited for massive scale studies. Flex APEX delivers these features at a lower cost per experiment and is enabling expanded access to single cell, driving increased reaction volumes and supporting broader adoption across our customer base."
Serge Saksonov, CEO and Co-founder
"Gross margin was 68% for the fourth quarter of 2025, as compared to 67% for the prior year period. The increase is primarily driven by lower inventory write downs, as well as lower royalty and warranty costs, partially offset by higher manufacturing costs. On the operating expense side, we continue to execute with a strong focus on operating efficiency and cost discipline."
Adam Tate, Chief Financial Officer
Strategic Positioning
1. Xenium-Led Spatial Expansion
Customer adoption is consolidating around Xenium, spatial biology platform, which now drives all spatial consumables growth. Management sees Xenium as the “best choice” for most spatial applications, and its robust utilization rates and customer expansion highlight a clear competitive moat. Visium, the legacy spatial platform, is now relegated to niche applications, with no growth in 2025 and limited forward emphasis.
2. Flex Apex and Volume-Driven Growth
Flex Apex, next-gen single-cell assay, is catalyzing double-digit reaction growth and opening new use cases, especially for large-scale AI and translational research. While pricing per experiment is lower, the strategy is to drive broader adoption and higher throughput, banking on volume to offset margin compression. Early adoption is strong, but management acknowledges the transition is in its early innings, with ongoing mix and pricing dynamics to monitor.
3. Translational and Clinical Market Push
TXG is actively expanding into translational research and clinical diagnostics, leveraging collaborations with major medical centers and biopharma. The company is building a CLIA lab, laboratory certified for clinical diagnostics, to accelerate diagnostic test deployment. This move aims to diversify revenue beyond academic research, with a long-term ambition for biopharma to drive up to half of total revenue over time.
4. Cost Discipline and Capital Allocation
Operating efficiency remains a core focus, as evidenced by an 18% reduction in operating expenses and a $130 million increase in cash. Management is using this financial flexibility to fund innovation and strategic expansion, while maintaining a buffer against ongoing funding uncertainty in core customer segments.
5. AI-Driven Demand as a Structural Tailwind
AI initiatives are a growing source of demand, with large-scale perturbation studies and virtual cell projects fueling consumables growth. Management sees no credible ceiling to data generation needs for AI model training in biology, positioning TXG as a foundational enabler for this secular trend.
Key Considerations
The quarter marks a turning point in TXG’s product mix and market focus, with spatial and single-cell consumables outpacing legacy instrument sales and new applications emerging in translational and AI-driven research.
Key Considerations:
- Spatial Portfolio Realignment: Xenium’s outperformance is leading to a de-emphasis of Visium, concentrating future growth and R&D investment on a single platform.
- Volume vs. Price Trade-Off: Flex Apex’s lower price point is expanding reaction volumes, but the net impact on revenue and margins will depend on the pace of adoption and customer mix.
- Translational and Clinical Scale-Up: Early-stage clinical collaborations and CLIA lab build-out could unlock new revenue streams, but require sustained investment and evidence generation.
- Regional Divergence: Weakness in US academic funding is partially offset by EMEA and APAC strength, but global funding volatility remains a risk.
- Balance Sheet Strength: Increased cash reserves provide resilience and optionality for strategic investments or M&A as the competitive landscape evolves.
Risks
Persistent funding uncertainty in academic and government markets, particularly in the US, continues to cloud instrument demand visibility and could delay recovery in capital equipment sales. Mix shift toward lower-priced consumables may pressure margins if volume growth does not fully offset ASP declines. Competitive threats in spatial and single-cell markets are rising, though management expresses confidence in innovation leadership. Regulatory hurdles and clinical adoption timelines introduce additional execution risk as TXG pushes into diagnostics.
Forward Outlook
For Q1 2026, TXG anticipates:
- First quarter revenue as a higher percentage of full-year, due to late Q4 orders shipped in January
- Continued CapEx constraints, with instrument sales under pressure
For full-year 2026, management reinstated guidance:
- Revenue of $600 million to $625 million, representing 0%–4% growth excluding litigation revenue in 2025
Management expects:
- Double-digit growth in single-cell consumables reactions and spatial consumables
- Operating efficiency gains to persist, supporting further cash generation
Takeaways
TXG’s Q4 results highlight a company in transition, with consumables-led growth, product innovation, and translational expansion offsetting persistent capital equipment headwinds.
- Xenium’s leadership in spatial is reshaping the portfolio, while Flex Apex’s volume surge is a double-edged sword for price/margin dynamics.
- Translational and clinical market entry is a strategic necessity, but will require sustained investment and careful execution to realize revenue potential.
- Investors should monitor the evolving balance between volume-driven growth and pricing/margin pressures, as well as the pace of recovery in instrument demand as funding clarity emerges.
Conclusion
10X Genomics enters 2026 with a strengthened consumables franchise and clear signals of market leadership in spatial biology, underpinned by disciplined cost management and translational ambitions. The path forward hinges on sustaining volume growth, navigating price/margin trade-offs, and capitalizing on emerging AI and clinical opportunities while weathering ongoing funding volatility.
Industry Read-Through
TXG’s results and commentary reinforce several sector-wide trends: the shift from instrument-driven to consumables-led revenue models, the outsized impact of CapEx funding cycles on life science tools, and the growing centrality of AI-driven research in driving demand for high-throughput assays. Competitors in spatial and single-cell genomics face an increasingly high bar for innovation and scale, while those with strong consumables portfolios and translational/clinical strategies are best positioned to weather macro volatility. Expect continued consolidation around leading platforms and heightened competition for the emerging clinical genomics dollar.